SOLID TUMOR, ADULT

This study tested a personalized vaccine made from each patient's unique cancer mutations (neoantigens) in 8 adults with advanced solid tumors or high risk of recurrence. The vaccine aims to train the immune system to recognize and attack cancer cells. Researchers checked for saf…

This early-stage study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The study is no…

This early-phase study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find safe doses and check for side effects. The study also looked…

This early-stage trial tested a new drug called GEN1056 in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for any signs that the drug might shrin…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The study looked at safety and how well the drug works, both alone and combined with o…

This study tested a new drug combination (ICT01 plus low-dose IL-2) in 56 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the combination is safe and can shrink tumors. The study also added a third drug (pembrolizumab) …

This early-stage study tested a new drug called DCR-STAT3 in 26 adults with solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study is now complete, and results will help decide if furt…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, or breast cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, but res…

This study tested a new drug called DF9001 in 24 adults with advanced solid tumors that have not responded to other treatments. The drug works by helping the body's immune cells attack cancer cells. The main goals were to check safety and see if the drug shrinks tumors, both when…

This study tested a drug called leronlimab in 16 adults with advanced solid tumors that have a specific protein (CCR5+). The main goals were to check safety and see if the drug could slow tumor growth. Participants had already tried other treatments or had no standard options lef…

This study tested a drug called HER3-DXd in 63 adults with breast or lung cancer that had spread to the brain or the lining around the spinal cord. Participants received the drug every three weeks. The goal was to see if it could shrink brain tumors and help people live longer. T…

This study tested whether adding a chemotherapy-like drug (thiopurine) to an immunotherapy (Atezolizumab) could help shrink advanced solid tumors that have spread. 18 adults with metastatic cancer that had no standard cure took part. The goal was to find the safest dose and see i…

This early-stage study tested a new drug called JNJ-64619178 in 114 adults with advanced cancers (like lymphoma, solid tumors, or myelodysplastic syndromes) that had not responded to other treatments. The main goal was to find the safest dose and check for side effects. The drug …

This early-stage study tested a new drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose for future studies. Participants took the drug daily, and resear…